Daisy has shown it can produce results in a volatile market, a sideways market, a market that crashed 50% and a market where most traders LOSt money. Endotech has attracted the interest of substantial institutional investment firms, their valuation has significantly increased, and is on track to enter new asset classes including forex, commodities and stocks all ensuring the IPO planned for 2022 will be a significant success.